Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Strong Long who wrote (1465)	8/22/2015 6:04:13 PM
From: mokelumne river	Respond to of 2026

Thanks SL. On the subject of SERMs, selective estrogen receptor modulators, I do think they are the future for secondary hypogonadism...and the latter is a big market. Repros has not played well with the FDA and there is probably fault on both sides. I am sure the FDA is anxious to approve an alternative to current testosterone therapy (gels and injections). If Fis can be approved (without delays) and capture part of that market, Apricus will do quite well. Like you, I and others here, invested years ago in the story of Vitaros. I still think V is a good story that was sullied by the Canada experience. Like Rob on iHub (and previously on YMB) explained, the licensing contracts were poorly drawn. That was Damaj's fatal error, and the retail investor's nightmare.